Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$2.73 - $4.92 $8,121 - $14,637
-2,975 Reduced 14.18%
18,000 $42,000
Q2 2022

Aug 15, 2022

BUY
$2.8 - $7.67 $23,755 - $65,072
8,484 Added 67.92%
20,975 $64,000
Q1 2022

May 16, 2022

BUY
$6.01 - $8.54 $31,816 - $45,210
5,294 Added 73.56%
12,491 $85,000
Q4 2021

Feb 14, 2022

SELL
$7.11 - $9.64 $31,141 - $42,223
-4,380 Reduced 37.83%
7,197 $60,000
Q3 2021

Nov 15, 2021

SELL
$5.04 - $8.73 $98,557 - $170,715
-19,555 Reduced 62.81%
11,577 $86,000
Q2 2021

Aug 16, 2021

BUY
$6.58 - $10.66 $21,575 - $34,954
3,279 Added 11.77%
31,132 $212,000
Q1 2021

May 17, 2021

BUY
$6.73 - $13.87 $187,450 - $386,321
27,853 New
27,853 $286,000
Q4 2020

Feb 16, 2021

SELL
$6.37 - $10.33 $345,075 - $559,596
-54,172 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.58 - $10.95 $248,107 - $593,183
54,172 New
54,172 $442,000
Q1 2020

May 15, 2020

SELL
$2.91 - $8.7 $8,127 - $24,299
-2,793 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$2.81 - $9.21 $7,848 - $25,723
2,793 New
2,793 $24,000
Q2 2018

Aug 14, 2018

SELL
$7.27 - $21.88 $78,974 - $237,682
-10,863 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$13.4 - $28.4 $145,564 - $308,509
10,863 New
10,863 $243,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.